Publications
- The translocation t(2;11)(p21;q23) without MLL gene rearrangement-a possible marker of good prognosis in myelodysplastic syndrome patients2014 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice2014 | First Faculty of Medicine
- Characterization of chromosome 11 breakpoints and the areas of deletion and amplification in patients with newly diagnosed acute myeloid leukemia2013 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Immunomodulation therapy - lenalidomide in the treatment of myelodysplastic syndrome in low-risk groups with deletion of the long arm of chromosome 52013 | First Faculty of Medicine
- TP53 mutations in myelodysplastic syndrome is significantly correlated with deletion of the long arm 5.chromozomu (5q-) and usually has a negative prognostic value (meaning TP53 examination in the era of lenalidomide)2013 | First Faculty of Medicine
- Deletion of the long arm but not the 5q31 region of chromosome 5 in myeloid malignancies2012 | First Faculty of Medicine
- 5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity2012 | First Faculty of Medicine
- Nature of frequent deletions in CEBPA2009 | First Faculty of Medicine
- Analysis of myelodysplastic syndrome patients with deletion of long arm of chromosome 5 followed up by the Czech MDS Working Group. Significance for the diagnostic and prognostic assessment2009 | First Faculty of Medicine
- Lenalidomide treatment of patients with 5q- syndrome affects genes located in the TNF pathwayPublication without faculty affiliation
Loading network view...